Topoisomerase I Inhibitor

5 Drugs classified under this drug class

Topoisomerase I Inhibitor. Irinotecan HCl 20 mg/ml.
CONC. FOR INFUS: 2 ml x 40 mg; 5 ml x
100 mg, 15 ml x 300 mg. Dosage should
be ajust. individ.
Tmt. of pts. with metastat. colorect.
cancer:
In comb. with 5-FU and folinic
acid in pts. without prior chemother. for
metastat. dis.
As a single agent in pts. who have failed
an established 5-FU contain.
tmt. regimen.
Tmt. of pts. with small cell lung canerc.
Tmt. of pts. with gastr. cancer.
Irinotecan in comb. with leucovorin and
5-FU for the first line
tmt. of pts. with metastatic pancreat.
adenocarcinoma.
C/I: Hypersens.
Chron. IBD and/or bowel obstruct.
Lact.
Bilirubin > 3 times the upper limit of the
normal range.
Severe bone marrow fail.
WHO performance status > 2.
Concom. use with St John’s Wort.
Live attenuat. vaccin.

Topoisomerase I Inhibitor. Topotecan HCl 0.25 mg, 1 mg.
HARD CAPS: 10 x 0.25 mg, 1 mg. See lit.
Tmt. pts with relapsed small cell lung
cancer (SCLC) when re-tmt. with first-line
regimen not approp.
C/I: Severe hypersens., pregn., lact.,
severe bone marrow depress. prior to
start. 1st course (baseline neutrophils
less than 1.5 x 10^9/L and/or placelet
count less than 100 x 10^9/L.

Topoisomerase I Inhibitor. Topotecan HCl 4 mg.
VIAL (for infusion): 1. Dose must adjust.
accord. to indication, blood counts and
pt’s medical condit. See it.
Metastat. carcinoma ovary where 1st -line
or subsequent ther. failed, small cell lung
cancer sens. dis. aft. fail. first line chemo.
In comb. with cisplatin: Stage IV-B recur./
persist. carcinoma cervix not amenable to
curative tmt. with surg. and/or radiat.
ther.
C/I: Hypersens., lact., pts. already have
severe bone marrow depress. prior to
starting 1st course, as evidenced by
baseline neutrophils < 1.5 x 109/l and/
or a platelet count of <100 x 109/l.

Topoisomerase I Inhibitor. Irinotecan HCl 20 mg/ml.
CONC. FOR INFUS: 2 ml x 40 mg; 5 ml x
100 mg, 25 ml x 500 mg. See lit.
Metastat. colorectal cancer either in comb.
with 5-fluorouracil and folinic acid in
patients without prior chemother. for
metastat. dis., or as single agent in pts.
who have failed an established
5-fluorouracil cont. tmt. regimen. Small
cell lung cancer, gastric cancer.
C/I: Chron. inflamm. bowel dis. and/or
bowel obstruct., hypersens., pregn., lact.,
bilirubin >3 times the upper limit of the
normal range, severe bone marrow
failure, WHO performance status > 2,
concom. use with St. John’s wort.

Topoisomerase I Inhibitor. Sacituzumab govitecan 200 mg.
Powd. for sol. for inf.:  Dose:10 mg/kg BW admin. as IV infus. 1/w on Day 1 and Day 8 of 21-day tmt. cycles.  Should be cont. until dis. progress. or unaccept. tox.
 Monother. for adlt. pts. with unresect. or metast. triple-negat. breast cancer (mTNBC) who received two or more prior syst. ther., incl. at least one of them for adv. dis.
C/I: Hypersens.